COVID-19 is an emerging, rapidly evolving situation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
NCL News Archive
Monday, April 13, 2020
Immunology Webinar Series
UPDATE--The online Immunology Workshop originally planned for June 8-12 and 15-18, 2020 has been reschdeuled to May 18-22, 25-28, 2020. The meeting time (11am-1pm EDT) and workshop agenda remain unchanged.
FREE Online Immunology Workshop
Molecular and Cellular Immunology: From Basics to Applications in Preclinical... View Post
Thursday, March 26, 2020
Bioequivalence Studies: Doxil vs Sun Pharma and Abraxane vs Genexol-PM
The NCL recently completed a 2.5 year interagency collaboration with the US Food and Drug Administration (FDA) to evaluate the bioequivalence of marketed nanomedicines. The complexity of nanomedicine drug formulations poses unique scientific challenges. And, with the influx of generic versions of several nanomedicines now nearing clinical evaluation, these formulations pose unique regulatory... View Post
Monday, March 9, 2020
New Assay Cascade Awardees Announced
The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post
Tuesday, February 25, 2020
New Funding Opportunity
Toward Translation of Nanotechnology Cancer Interventions (TTNCI), PAR-20-116
The National Cancer Institute has just posted a new funding opportunity entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)". TTNCI is meant to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/... View Post
Wednesday, February 5, 2020
Upcoming Application Deadline - March 2, 2020
The next deadline for application to NCL’s Assay Cascade characterization program is March 2, 2020. Visit our application and instructions page to download the template and review the evaluation criteria: https://ncl.cancer.gov/working-ncl/ncl-assay-cascade-application-process
Have questions about the application, evaluation criteria, or the overall process? Please... View Post
Wednesday, October 16, 2019
NCL Leadership Changes
The NCL is proud to announce the appointment of Drs. Marina Dobrovolskaia and Stephan Stern as Laboratory Co-Directors. Dr. Dobrovolskaia will serve as Director of Operations for the lab, and Dr. Stern will serve as Director of Research & Development for the lab.
NCL will continue to support nanotech developers in their translational efforts by offering characterization and... View Post
Wednesday, October 16, 2019
NCL Assay Cascade—Back to Quarterly Application Deadlines
By popular request, the NCL will revert back to quarterly deadlines for the NCL’s Assay Cascade characterization service. The quarterly deadlines will be the first business days of March, June, September and December. The next application deadline will be December 2, 2019. For questions on the application process, email us at ncl@mail.nih.gov.
Wednesday, October 16, 2019
Funding Opportunities & Translational Resources
The National Cancer Institute’s Nanodelivery Systems and Devices Branch has compiled the following list of funding opportunities and translational resources that may be of interest to nanotech developers. Click the link for each announcement to learn more.
Nanotechnology-Focused:
PAR 20-284 – Innovative Research in Cancer Nanotechnology (R01... View PostFriday, September 27, 2019
Online Workshop - Molecular & Cellular Immunology
FREE Online Workshop
MOLECULAR AND CELLULAR IMMUNOLOGY: FROM BASICS TO APPLICATIONS IN PRECLINICAL DEVELOPMENT OF NANOTECHNOLOGY-FORMULATED DRUGS
December 2-6 and 9-12, 2019—11am-1pm EST
This two-part on-line workshop includes lectures covering fundamental... View Post
Friday, August 16, 2019
August 2019 Awardees Announced
The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post